The main aim of newborn blood spot screening is to identify infants with disease states of sickle cell disease (SCD) 7 to ensure early treatment (1 ). In the UK, HPLC and isoelectric focusing (IEF) are currently used as the acceptable screening technologies (1 ). As a consequence of the use of methods originally designed for the diagnostic investigation of hemoglobinopathies, both disease and carrier states along with other benign hemoglobin (Hb) variants are all identified, requiring further confirmatory testing and referral to genetic counseling services. In 2011-2012, approximately 10 000 sickle carrier infants were identified and referred for follow-up in England (2 ) . The detection of sickle cell carrier states as a byproduct of newborn screening is of questionable clinical significance and has the potential to cause psychosocial harm by the exposure of nonpaternity, the risk of stigma and discrimination, and anxiety about future health (3, 4 ) , as well as having significant cost implications.
Tandem mass spectrometry (MS/MS) has been explored as an alternative screening technology for SCD because it detects Hb peptides following digestion of blood spots with trypsin (5 ), which results in the formation of 15 reproducible peptides of the wild-type HbA ␤-chain (␤T1-15) (6 ) . Mutations generate pep-tides specific to the mutation present, with mutations for the HbS and C variants located in the ␤T1 peptide, HbE in the ␤T3 peptide, and O Arab and D Punjab in the ␤T13 peptide (5, 6 ) . A study involving the analysis of 40 406 newborn blood spots by MS/MS correctly identified all the clinically relevant Hb variants (7 ) . MS/MS has been used routinely in Belgium since 2008 to screen newborns for SCD (8, 9 ) . However, the MS/MS protocols used previously referred those samples identified with increased HbS peptide abundances for secondline testing, thereby identifying both disease and carrier states. The potential utility of the specific variant to wild-type Hb peptide ratios to distinguish samples from individuals with normal Hb or carrier and disease states of SCD has been reported (5, 9 ) . However, the utility of these ratios to identify only the disease states of SCD and not to identify carrier states as part of a screening protocol has not been formally evaluated.
The Human Genetics Commission recommends that caution should be observed in the testing of children when they may not benefit directly, and that efforts be made to develop screening techniques that do not reveal carrier status unless this would compromise the reliability of the test, or the information about this status is clinically important to the child's health (10 ) .
The purpose of this study was to establish cutoffs for the specific variant to wild-type Hb peptide ratios using MS/MS and to develop a protocol to identify only the disease states of SCD in a routine newborn screening laboratory.
Methods

ANALYSIS OF Hb PEPTIDES IN BLOOD SPOTS BY MS/MS
The work undertaken here was a service evaluation and included anonymized residual samples. Blood spots were punched (3.2 mm) into 96 deep-well polypropylene plates (Porvair Sciences). Hb peptides were assayed by MS/MS following tryptic digestion of extracts from dried blood spots in accordance with the SpOtOn Clinical Diagnostics protocol (11, 12 ) . The kit contains a stable isotope HbS peptide internal standard that reveals itself only following trypsin digestion and acts as a control for the digestion step. Samples (10 L) were introduced in acetonitrile:water (1:1) containing 0.025% formic acid flowing at 150 L/min (Acquity UPLC) into a Waters Xevo-TQ MS/MS with an electrospray source in positive ionization mode. Multiple reaction monitoring acquisitions were as described (11 ) analysis time was 120 s/sample. A postinjection wash cycle was included to prevent any sample carryover. MS/MS data acquisition was achieved by using 3 different functions within the Waters NeoLynx software. Function 1 was used to collect the internal standard abundance (to accept/reject samples) and the HbF and HbA(␤T1-3) peptide abundances and the appropriate ratios to assess for transfusion status and prematurity. Functions 2 and 3 were used to collect the remaining peptide transition abundances and the specific variant to wild-type Hb peptide ratios.
All data were exported to Microsoft Excel 2003 for analysis and centiles for the relevant peptide abundances and ratios were calculated using the SPSS statistical package (SPSS v16).
ASSESSMENT OF ASSAY PERFORMANCE
The assay and the postanalytical data analysis protocol developed were quality assured by the addition of QC samples containing different amounts of the variant Hb peptides, and analyzed with every batch of samples. QC samples were prepared by mixing residual liquid blood samples from individuals with confirmed Hb variant disorders and then pipetting 25 L of blood spot onto PerkinElmer 226 filter paper (PerkinElmer). Due to the rarity of the HbO Arab and HbLepore variants, to validate the detection of these peptides we prepared liquid QC samples by pooling and mixing blood spot extracts.
The limit of detection of the method was assessed by analyzing blood spots prepared from sequential dilutions of a residual liquid blood sample from an adult patient with SCD (HbSS) in an anonymized residual liquid cord blood sample (HbAA). Two separate series of blood spot samples were prepared and analyzed by both MS/MS and HPLC (Bio-Rad Variant™ II, short ␤-thalassemia kit). Sample carryover was assessed by the analysis of the HbS peptide in blood spot samples from newborns without an Hb variant, following the analysis of blood spot samples from HbSS newborns.
GENERATION OF SCREENING CUTOFFS TO DETERMINE Hb
VARIANT PHENOTYPES
Analyses of anonymized residual newborn blood spots were used to generate cutoffs for the various variant: wild-type Hb peptide ratios. A total of 2154 routine newborn blood spots received into the Wales Newborn Screening Laboratory (low prevalence region for SCD) were used to define the normal Hb infant group. Newborn blood spot samples from 675 infants diagnosed as having an Hb variant were also analyzed and comprised the following phenotypes: Arab adult carriers were used to demonstrate the ability of the assay to identify carrier individuals. Eighteen routine blood spot samples received that were marked as transfused on the card were also analyzed.
Centiles (0.1st, 1st, 2.5th, 50th, 97.5th, 99th, and 99.9th) for the Hb variant:wild-type peptides were calculated for those samples from normal Hb infants (n ϭ 2154) and the HbS carrier infants (n ϭ 387). Cutoffs for the other Hb variants, both carrier and diseased states (heterozygous and homozygous states), were calculated as the lowest and highest ratios observed.
ASSESSMENT OF Hb PEPTIDES TO DETECT SAMPLES FROM PREMATURE AND TRANSFUSED INFANTS
Using data from the normal Hb infant group the A(␤T1):F ratio and the gestational age (GA) of the infant were correlated to provide information on the expected amounts of HbA and HbF for the GA of the infant. The ability of the MS/MS system to detect the Hb variants in premature infants was assessed by comparing the S:A ratio obtained in blood spots from premature infants (GA, Ͻ36 weeks) to those from term infants. To identify blood spots from premature or transfused infants, we calculated cutoffs for the A(␤T1):F, F:A(␤T2), and A(␤T3):F ratios using data from the normal infant group. Eighteen routine newborn blood spot samples that were marked as transfused were also analyzed and the various HbA and HbF ratios calculated.
PARALLEL STUDY OF HPLC vs MS/MS
To validate the screening cutoffs and postanalytical protocol developed, we undertook a study to compare results obtained by the analysis of samples from the same newborn by both HPLC (Variant™ NBS; BioRad Laboratories) and MS/MS. The parallel study was undertaken with the Newborn Screening Laboratory at the Great Ormond Street Hospital, London, during October 2012 because the population it screens has a higher prevalence of SCD than the population of Wales. Consecutive newborn blood spot samples received were punched (3.2 mm) into 96 deep-well plates and then transported to the Wales Newborn Screening Laboratory on a weekly basis for analysis. from 3.5% to 10.9% and 8.9% to 21.2%, respectively ( Table 2 ). The %HbS values determined by HPLC ranged from 39.1% to 1.7%, with the S:A ratio ranging from 3.4 to 0.1 in the first sample dilution series and 8.6% to 0.7% (S:A ratio, 0.74 -0.06) in the second sample dilution series. The sample carryover of the HbS peptide for the 8 separate series of samples ranged from 0% to 0.4%. Fig. 1 shows the mean (1st and 99th centiles) for the peptide ratios in the normal Hb and HbS carrier infants and the mean (lowest and highest ratio observed) for the various Hb variant phenotypes and transfused infants. The peptide ratios distinguished between the normal, carrier, and disease/homozygous states. Furthermore, the A(␤T1):F and F:A(␤T2) ratios clearly identified those cases of ␤-thalassemia from the normal Hb infant group. The A(␤T3):F ratio was able to identify the HbE/␤-thalassemia cases because the HbE mutation is located on the ␤T3 peptide, and in conjunction with the ␤-thalassemia carrier state a low/absent ratio is observed.
SCREENING CUTOFFS TO DETERMINE Hb VARIANT PHENOTYPES
POSTANALYTICAL DATA PROTOCOL TO IDENTIFY THE DISEASE
STATES OF SCD
Using the cutoffs generated, a postanalytical data protocol was developed to identify only the disease states of SCD (Fig. 2) . MS/MS acquisition data were exported into Excel and then analyzed using a developed inhouse macro program. The macro sorted the QC samples from the routine screening samples and then analyzed the peptide abundances and ratios. Only the internal standard, A(␤T1-3), and HbF peptide abundances and corresponding ratios to HbF were revealed to check for sample integrity, prematurity, and transfusion status. All other data were locked (password protected) and were not able to be viewed. The following cutoffs (lower to upper) were used in the parallel study to identify any sample(s) that required further action or referral. Cutoffs for the peptide abundances were based on the 1st and 99. To identify cases of HbSS, HbS/C, HbS/␤-thalassemia, or HbS/HPFH, the macro identified and flagged those samples with an S:A ratio of Ն2.1. This cutoff was based upon the 99th centile of 387 HbS carriers. To identify those samples with an HbS variant peptide in conjunction with an additional interacting Hb variant peptide, an S:A cutoff of Ն0.10 but Ͻ2.1 (99.9th centile of the normal Hb infant group and 99th centile of the HbS carrier infant group) was used, which then triggered the macro to search additional data columns to identify a raised ratio indicating the presence of an additional variant (i.e., HbS/C, HbS/ D Punjab , HbS/E, HbSO Arab and HbS/Lepore) and if identified, the sample was flagged to alert the laboratory scientist (see (Fig. 1) .
PARALLEL STUDY
A total of 13 249 samples were analyzed by the MS/MS screening protocol and these data were then compared to those obtained by HPLC (Table 3 ). All 7 cases of the To complete this validation study, the excel macro data sheets were unblinded and a total of 328 carrier infants were revealed [234 HbS (S:A ratios, 0.55-2.0), 36 HbC (C:A ratios, 1.15-4.4), 43 HbE (E:A ratios, 1.18 -3.11), and 15 HbD Punjab (D:A ratios, 1.37-2.24)]. To further assess the protocol outlined, 19 anonymized and blinded residual newborn blood spot samples from infants with a confirmed diagnosis of SCD, ␤-thalassemia, HbE/␤-thalassemia, and homozygous HbCC were provided by the Newborn Screening Laboratory at Birmingham Children's Hospital. All cases were correctly classified using the amended cutoffs (Table 4) 
Discussion
Previous studies using MS/MS to detect Hb variants in blood spot tryptic digests have identified both the disease and carrier states (7, 9 ) . Experience is limited with the use of the peptide ratios to distinguish between infants with disease states, carrier states, and normal Hb (5, 9 ) , and the use of these ratios to identify only the disease states of SCD has not been previously evaluated. In this study we have demonstrated the utility of the variant to corresponding wild-type Hb peptide ratios to distinguish between infants with disease states, carrier states, and normal Hb. The distinction between the HbD Punjab carrier infants and the normal Hb infant group using the D Punjab :A ratio cutoff was less well resolved. These ratios were based on samples classified by HPLC/IEF, without molecular confirmation, and inclusion of samples from other HbD variants may have caused the skewing of these cutoffs. In addition, the D Punjab mutation has a mass shift of 0.5 Da from the wild-type peptide, and the resolution of this small mass difference in the blood spot matrix may also have affected the ratio determination. However, no falsepositive cases of HbS/D Punjab were identified in the parallel study.
A confounding problem in newborn screening for SCD is the low expression of the HbA ␤-chains in the first week of life, particularly in premature infants. Additionally, the presence of transfused blood in new- borns also affects the results obtained. Therefore, it is essential that the screening method can identify samples from infants that are premature or have had a transfusion. To identify such samples, the proportion of HbA and HbF present was assessed by the calculation of the A(␤T1):F, F:A(␤T2), and A(␤T3):F ratios. The amount of HbF varies according to GA, and the calculation of the A(␤T1):F ratios at the various GA time points provides information on the expected ratio for the GA of the infant. Samples from infants with a low/absent A(␤T1&3):F ratio and decreased ␤T1-3 peptide abundances should be followed up to ensure detection of ␤-thalassemia. Overlap in the A:F ratios was observed between those samples marked as transfused and those in the normal Hb infant group (nontransfused), a finding that is also observed with the existing technologies for Hb variant analysis. Those samples identified with increased A(␤T1):F and A(␤T3):F ratios and a low F:A(␤T2) ratio should be referred for HbS mutation testing or repeat testing on a sample collected 3 months after the last transfusion to ensure that cases of SCD are not missed. However, the analytical process outlined to identify samples from transfused and premature infants will also result in the identification of cases of ␤-thalassemia major/intermedia [low A(␤T1):F ratio] and HbE/␤-thalassemia [low A(␤T3):F ratio], HbCC and HbC/␤thalassemia (low ␤T1 peptide resulting in a falsely increased S:A ratio of Ն0.1 but Ͻ2.1 and a raised C:A ratio) as byproducts similar to the existing technologies. Rare variants may also occur on the ␤T1, 3, and 13 peptides and may result in a false-positive result. It is therefore important that a second-line test is used to confirm all screen-positive results.
In the parallel study of 13 249 newborn blood spot samples from a high-prevalence area for SCD in the UK, no false-negative cases were identified, and all clinically relevant cases were correctly classified. However, 8 false-positive cases were identified (6 HbS/C and 2 HbSS). The 6 false-positive HbS/C cases were HbS carrier infants, and it was evident that the C:A ratio cutoff (Ն0.30) used, which was based upon the 99.9th centile observed in 2154 normal Hb infants, was too low. The ratio cutoff was subsequently increased to Ն0.50 and resulted in these 6 cases being correctly classified as not having SCD. This increase in ratio was made on the basis of the observation that the C:A ratios in the HbC carrier infants (n ϭ 97) ranged from 1.19 to 4.61 and 25.5 to 263.0 in the HbS/C cases (n ϭ 15).
The 2 false-positive HbSS cases identified were HbS carrier infants with S:A ratios just above the cutoff of Ն2.1 and were lower than those observed in the HbSS/HbSC group (Fig. 1) . However, only a few samples from cases of HbS/␤-thalassemia major/intermedia and HbS/HPFH have been analyzed by our protocol. Therefore, until further data are available, the pragmatic S:A ratio cutoff of 2.1 should ensure the detection of HbSS, HbS/C, HbS/HPFH, and HbS/␤-thalassemia major/intermedia cases at the expense of identifying minimal false-positive HbS carrier infants. To further assess the testing protocol devised, additional blinded newborn blood spot samples from infants with a confirmed diagnosis of HbSS, HbS/C, HbS/HPFH, HbS/ ␤-thalassemia, and HbE/␤-thalassemia were also analyzed using this MS/MS protocol and were also correctly classified.
The MS/MS assay for the routine analysis of Hb peptide ratios in newborn blood spots was reproducible, with assay CVs similar to those reported previously (8 ) . However, the development of synthetic stable isotope variant Hb peptides would improve the imprecision of the assay and provide a means of standardization across MS/MS instruments. Further work is required to assess the transferability of these screening cutoffs onto other MS/MS platforms. Comparison of the ratios obtained in our study to those reported by others cannot be made, because the only study to report on such ratios in newborn blood spots required the use of multiple ion transitions to ensure the detection of the various peptides (8 ) . The MS/MS instrument used in our study was analytically sensitive enough to detect the various peptides by use of single ion transitions in blood spots from premature infants and also HbS peptides in blood spots at concentrations Ͻ1% of the total Hb present. However, the use of multiple ion transitions may be required to detect the various peptides when using less sensitive MS/MS platforms (8 ) . The adoption of MS/MS as a common platform within newborn screening laboratories for the nonimmunoassay tests allows the cost-effective use of equipment/expertise that currently exist in these laboratories because the screening for inborn errors of metabolism and SCD can be performed consecutively.
In conclusion, we have developed a newborn blood spot screening protocol that uses MS/MS to detect only the disease states of SCD. This protocol was found to be robust for routine screening use and reduces the cost of the screening program by preventing large numbers of carrier infants from being identified and avoiding unnecessary follow-up testing and referral for genetic counseling.
The protocol outlined in this manuscript has been endorsed by the UK National Screening Committee for implementation in Wales (13 ) and this protocol was implemented in Wales, UK, on June 1, 2013. 
